Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chardan Adjusts Price Target on Kaleido Biosciences to $11 From $15 on Pipeline Assets Update, Maintains Buy Rating

11/12/2021 | 08:48am EST


ę MT Newswires 2021
All news about KALEIDO BIOSCIENCES, INC.
2021KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from NASDAQ Biotechnology Index
CI
2021Kaleido Biosciences Expands and Extends Collaboration With Janssen
MT
2021Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potent..
GL
2021Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potent..
CI
2021Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ..
GL
2021Chardan Adjusts Price Target on Kaleido Biosciences to $11 From $15 on Pipeline Assets ..
MT
2021Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer
GL
2021Kaleido Biosciences, Inc. to Appoint Alison Long as Chief Medical Officer, Effective De..
CI
2021JMP Securities Adjusts Price Target on Kaleido Biosciences to $22 From $25, Maintains M..
MT
2021KALEIDO BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
More news
Analyst Recommendations on KALEIDO BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 1,61 M - -
Net income 2021 -94,6 M - -
Net cash 2021 5,83 M - -
P/E ratio 2021 -0,98x
Yield 2021 -
Capitalization 94,1 M 94,1 M -
EV / Sales 2021 55,0x
EV / Sales 2022 57,6x
Nbr of Employees 82
Free-Float -
Chart KALEIDO BIOSCIENCES, INC.
Duration : Period :
Kaleido Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALEIDO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 2,21 $
Average target price 14,80 $
Spread / Average Target 570%
EPS Revisions
Managers and Directors
Daniel L. Menichella President, Chief Executive Officer & Director
William E. Duke Chief Financial Officer
Theo Melas-Kyriazi Chairman
Johan van Hylckama Vlieg Chief Scientific Officer
Kimberly Hocknell Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
KALEIDO BIOSCIENCES, INC.-7.53%94
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684